Cargando…
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minima...
Autores principales: | Oliva, Stefania, Gambella, Manuela, Gilestro, Milena, Muccio, Vittorio Emanuele, Gay, Francesca, Drandi, Daniela, Ferrero, Simone, Passera, Roberto, Pautasso, Chiara, Bernardini, Annalisa, Genuardi, Mariella, Patriarca, Francesca, Saraci, Elona, Petrucci, Maria Teresa, Pescosta, Norbert, Liberati, Anna Marina, Caravita, Tommaso, Conticello, Concetta, Rocci, Alberto, Musto, Pellegrino, Boccadoro, Mario, Palumbo, Antonio, Omedè, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351601/ https://www.ncbi.nlm.nih.gov/pubmed/27779105 http://dx.doi.org/10.18632/oncotarget.12641 |
Ejemplares similares
-
Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
por: Drandi, Daniela, et al.
Publicado: (2018) -
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020) -
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020) -
Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017) -
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
por: Castella, Barbara, et al.
Publicado: (2015)